𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Response to botulinum toxin F in seronegative botulinum toxin A—resistant patients

✍ Scribed by Dr. Paul E. Greene; Stanley Fahn

Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
342 KB
Volume
11
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Botulinum toxin type A (btx A) injections are the most effective treatment for most patients with focal dystonia. Some patients who improve after btx A injections and later lose response have serologic evidence of antibodies to btx A with the mouse neutralization assay (seropositive patients). Another group of patients who lose response to btx A do not have detectable antibodies (seronegative patients). Seropositive patients may improve after injections of botulinum toxin type F (btx F), an alternative serotype of botulinum toxin. We treated nine seronegative resistant patients with btx F. None of these patients had muscle atrophy after injection with btx A. Five of the nine had improvement after btx F injection that was sustained for at least three consecutive btx F injections. This observation is consistent with the hypothesis that btx resistance in seronegative patients is caused by undetected antibodies to btx A. If this be the case, then there may be techniques for preventing or reversing btx resistance, as in the case of resistance to factor VIII in the treatment of hemophilia A.

📜 SIMILAR VOLUMES

Use of botulinum toxin type F injections
Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A
✍ Dr. Paul E. Greene; Stanley Fahn 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 492 KB

## Abstract Fifteen patients with torticollis who had been treated with repeated injections of botulinum toxin type A (botox A) developed antibodies to the toxin. This resulted in loss of benefit in the 13 patients who had improved with botox A injections and failure to develop muscle atrophy after

Development of resistance to botulinum t
Development of resistance to botulinum toxin type A in patients with torticollis
✍ Dr. Paul Greene; Stanley Fahn; Beverly Diamond 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 453 KB

## Abstract Between 1984 and 1992, 559 patients with torticollis were treated with botulinum toxin type A (btx) injections. Twenty‐four of these 559 patients (4.3%) had serological evidence of antibodies to btx by mouse neutralization assay. Some of the 559 patients had only one or two injection se

BotB (botulinum Toxin type B): Evaluatio
BotB (botulinum Toxin type B): Evaluation of safety and tolerability in botulinum toxin type A-Resistant cervical dystonia patients (preliminary study)
✍ Dr. Daniel D. Truong; Paul A. Cullis; Christopher F. O'Brien; Martin Koller; Tim 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 314 KB

## Abstract Botulinum toxin (BTX) injection is considered the treatment of choice for patients with cervical dystonia (torticollis). We conducted a pilot, open‐label, dose‐escalation study with BTX type B in 12 patients who no longer responded clinically to injections with BTX type A. At the doses

Secondary nonresponsiveness to botulinum
Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia
✍ Charles H. Adler; Stewart A. Factor; Mitchell Brin; Kapil D. Sethi 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

## Abstract Intramuscular injection of botulinum toxin type A is the treatment of choice for most cases of oromandibular dystonia. We report on five patients with oromandibular dystonia that developed secondary nonresponsiveness to botulinum toxin type A following multiple injections over a 6‐year